|This TandAb recognizes Epidermal Growth Factor Receptor variant III (EGFRvIII) on the tumor cell and utilizing its second functionality binds with high affinity to T-cells and activates them. EGFRvIII is a splice variant of the wild-type EGF receptor (EGFR-wt) which is the target of several anti-cancer products. In contrast to EGFR, Variant III is a unique target on tumor cells with little risk of T-cell activation due to binding to healthy tissue. EGFRvIII is expressed by many solid tumor
|| entities and is strongly associated with glioblastoma, head and neck cancer, as well as prostate cancer. In North America, the EU and Japan, as many as 500,000 patients are affected by these diseases. Affimed has succeeded in generating TandAbs that are highly specific for the variant and that do not bind EGFR-wt. The project is currently entering preclinical development.